IGEA works to improve patient’s quality of life, developing and producing, from its original projects, innovative, effective and safe therapeutic systems for clinical practice.
IGEA develops biophysical treatments in two main areas: 1) orthopedics, to improve bone healing and joint preservation and 2) oncology, to treat cancer. The Cliniporator® and the Cliniporator® VITAE are the most advanced electroporation technologies for the treatment of tumor nodules located into the skin, subcutaneous tissue, parenchyma and bone.
Atlante Ventures invested in Igea in 2008. IGEA’s founders bought back Atlante Ventures’ shares in 2016.